Physician profile
Amy Kehl
NPI 1679879555
$8,109.20
in general payments reported to CMS, 2019-2025
30 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $913 · 2023: $2,905 · 2024: $2,808 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,068 · Education: $117 · Travel and Lodging: $10.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,068.40 |
| Education | $117.25 |
| Travel and Lodging | $10.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,844.72 | 2022-2025 | |
| Amgen INC. | $1,279.14 | 2022-2025 | Enbrel, Evenity, Tavneos |
| Glaxosmithkline, LLC. | $795.77 | 2022-2025 | Benlysta, Trelegy Ellipta |
| Janssen Biotech, INC. | $731.98 | 2023-2025 | Tremfya, Remicade, Simponi Aria |
| Ucb, INC. | $649.72 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $456.83 | 2022-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $393.86 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.70 | 2022-2024 | Cyltezo, Spevigo, Jardiance |
| Mallinckrodt Hospital Products INC. | $232.97 | 2023-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $228.66 | 2022-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $209.42 | 2024-2025 | Orencia |
| Octapharma USA, INC. | $175.61 | 2023 | Panzyga, Octagam Immune Globulin (Human) |
| Pfizer INC. | $138.95 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $112.92 | 2024-2025 | |
| Bioventus LLC | $109.84 | 2023-2025 | Durolane, Durolane, Xcell |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $64.17 | 2023 | Idacio |
| Kiniksa Pharmaceuticals, LTD. | $46.18 | 2023 | Arcalyst |
| Radius Health, INC. | $43.24 | 2024 | |
| Celltrion USA INC. | $37.26 | 2023 | Yuflyma |
| Ani Pharmaceuticals, INC. | $33.05 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $27.58 | 2024 | Ultomiris |
| Opko Pharmaceuticals, LLC | $27.42 | 2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $27.11 | 2024 | |
| Alvogen INC | $22.48 | 2023 | Teriparatide |
| Horizon Therapeutics Plc | $20.59 | 2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $19.90 | 2023 | Xarelto |
| Novo Nordisk INC | $18.32 | 2024 | Rivfloza |
| Genentech USA, INC. | $17.88 | 2025 | Actemra |
| Depuy Synthes Sales INC. | $16.11 | 2023 | Monovisc |
| Abbott Laboratories | $14.82 | 2025 | Eterna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Kehl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.